N-hydroxyphthalimide and phthalimide precursors for novel dxr-targeting antibiotic development

Overview

This research program focuses on the synthesis and application of N-hydroxyphthalimide and phthalimide derivatives as precursors for inhibitors targeting DXR (1-Deoxy-D-xylulose-5-phosphate reductoisomerase), a critical enzyme in the non-mevalonate pathway of bacterial isoprenoid biosynthesis. Because this pathway is essential in many pathogenic bacteria but absent in humans, DXR represents a promising target for novel antibiotics addressing antimicrobial resistance. The precursor compounds incorporate key pharmacophoric elements found in known DXR inhibitors, including protected phosphonic acid groups and precursors to hydroxamic acid moieties, making them valuable starting materials for medicinal chemistry campaigns aimed at developing new antibacterial agents.

Technical specifications

Key features:

• N-hydroxyphthalimide and phthalimide scaffolds serving as versatile precursors for DXR inhibitor synthesis
• Incorporation of protected phosphonic acid functionalities relevant to DXR active-site binding
• Hydroxamic acid precursors compatible with established DXR inhibitor pharmacophore models
• Synthetic routes designed to enable structure-activity relationship (SAR) exploration
• Compounds relevant to targeting the methylerythritol phosphate (MEP) pathway in Gram-negative and other bacteria

Potential applications:

• Lead generation for novel antibacterial drug discovery
• Medicinal chemistry optimization campaigns against drug-resistant pathogens
• Academic and industrial antimicrobial resistance research programs

Technology readiness level

The research is at an early-to-mid stage of preclinical investigation. Synthetic routes for the precursor compounds have been developed, and the underlying hypothesis—that these phthalimide-based precursors can yield effective DXR inhibitors—requires further experimental validation through enzyme inhibition assays and antibacterial activity testing. The program is positioned for collaborative partnerships to advance compound evaluation, medicinal chemistry optimization, and downstream biological validation.